ZT-12-037-01 manufacturers
- ZT-12-037-01
-
- $30.00 / 1mg
-
2025-12-05
- CAS:2328073-61-4
- Min. Order:
- Purity: 99.56%
- Supply Ability: 10g
|
| | ZT-12-037-01 Basic information |
| Product Name: | ZT-12-037-01 | | Synonyms: | ZT-12-037-01;2,4-Quinazolinediamine, N2-cyclopropyl-6,7-dimethoxy-N4-[1-(1-methylethyl)-4-piperidinyl]-;inhibit,ZT 12 037 01,ZT1203701,Ras,Inhibitor;N2-Cyclopropyl-N4-(1-isopropylpiperidin-4-yl)-6,7-dimethoxyquinazoline-2,4-diamine;ZT-12-037-01, 10 mM in DMSO | | CAS: | 2328073-61-4 | | MF: | C21H31N5O2 | | MW: | 385.5 | | EINECS: | | | Product Categories: | | | Mol File: | 2328073-61-4.mol |  |
| | ZT-12-037-01 Chemical Properties |
| storage temp. | 2-8°C(protect from light) | | solubility | DMSO: 8.33 mg/mL (21.61 mM) | | form | Solid | | color | White to off-white |
| | ZT-12-037-01 Usage And Synthesis |
| Uses | ZT-12-037-01 is a STK19-targeted inhibitor, has a high-affinity interaction with STK19 protein and inhibits oncogenic NRAS-driven melanocyte malignant transformation. ZT-12-037-01 is an ATP-competitive inhibitor, inhibiting phosphorylation of NRAS (major isoform of Ras family) with an IC50 of 24 nM[1]. | | Biological Activity | ZT-12-037-01 is an ATP-competitive STK19 inhibitor with IC50 values of 23.96 nM and 27.94 nM for STK19 (WT) and STK19 (D89N), respectively. At a concentration of 1 μM, it is highly selective against a kinase library of 468 kinases. | | in vitro | Treatment with ZT-12-037-01 could effectively inhibit NRAS phosphorylation. ZT-12-037-01 is an ATP-competitive inhibitor that potently inhibits melanocytic colony formation, proliferation and tumor formation driven by mutant NRAS-STK19. It's pro-apoptotic activity was significantly enhanced in cells expressing oncogenic NRAS. | | in vivo | ZT-12-037-01 is a potent STK19 inhibitor with low toxicity in vivo. In the SK-MEL-2 xenograft model (carrying NRAS. | | target | | Target | Value | STK19
(Cell-free assay) | 23.96 nM | STK19 (D89N)
(Cell-free assay) | 27.94 nM | < /table>| References | [1] Yin C, et al. Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis. Cell. 2019 Feb 21;176(5):1113-1127.e16. DOI:10.1016/j.cell.2019.01.002 |
| | ZT-12-037-01 Preparation Products And Raw materials |
|
|
Tag:ZT-12-037-01(2328073-61-4)
Related Product Information
|
|
Z-Vad-fmk, non-methylated
(Z)-CAPSAICIN
ZSTK474
Z-VAD-FMK
|
According to the laws, regulations and policies related to "patent products", the sale of this product is prohibited!
ChemicalBook prompt
The patent owner or licensee of the product has not released any relevant information for the time being.
|